Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Randomized, Double-blind, 5-arm Parallel Group, Placebo Controlled 4 Week Study to Investigate the Safety, Tolerability and Efficacy of Two Doses Each (Near to Maximum Tolerated Dose and Lower Dose) of RO5093151 Administered Twice Daily (BID Regimen) and RO5027838 Administered Once da

NCT00823680 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00823680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00823680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Randomized, Double-blind, 5-arm Parallel Group, Placebo Controlled 4 Week Study to Investigate the Safety, Tolerability and Efficacy of Two Doses Each (Near to Maximum Tolerated Dose and Lower Dose) of RO5093151 Administered Twice Daily (BID Regimen) and RO5027838 Administered Once da
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
August 31, 2009
Enrollment
110 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2